Updates in the Management of Stage IV NSCLC

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session at the 2017 Spring Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from June 15, 2017 to August 1, 2018

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.  To print or save your certificate, you will need to click on the “download” button and either print or save.

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This educational activity is supported by educational grants from
AstraZeneca, Genentech, Lilly USA LLC, and Merck & Company

Lung cancer is the second most common cancer in both men and women and accounts for approximately 80% of all cancer cases. The use of histologic subtypes and molecular biomarker assessment in non-small cell lung cancer (NSCLC) has resulted in therapeutic paradigms that can be optimized for individual patients based on unique characteristics of their cancer. The concept of tailoring therapies based on clinical and molecular markers has transformed the management of advanced NSCLC, but also complicated the treatment paradigm, as there are many possible options for each individual patient. Additionally, more agents have recently been approved, with some undergoing regulatory review, for advanced anaplastic lymphoma kinase positive (ALK+) NSCLC, which have shown the ability to help increase prognosis, survival and quality of life in NSCLC. Healthcare professionals (HCPs) need to be aware of information regarding tumor-specific diagnosis, expanding treatment options, and supporting data to maximize the care of their patients.

Upon Completion of this activity, participants will be able to:

  • Review the safety and efficacy profiles of approved and investigational therapies for advanced NSCLC, including targeted and immunologic agents

  • Assess the latest guideline recommendations and clinical data surrounding recently approved and emerging therapies in advanced ALK+ NSCLC and EGFR-Mutated NSCLC with disease progression

  • Analyze the roles of biopsy, histology, and molecular testing in subtyping and treatment decision-making in advanced NSCLC

  • Describe disease-specific and individual factors that should be considered when choosing pharmacotherapy for NSCLC

  • Identify strategies for prevention, detection, and optimal management of adverse effects in patients undergoing treatment for advanced NSCLC, to ensure that patients maintain high level quality of life while completing the selected therapy

  • Analyze management strategies for patients with advanced EGFR NSCLC who develop a T790M resistance mutation

  • Examine emerging technologies and key clinical considerations on the use of rebiopsy or liquid biopsies as methods to identify actionable mutations in advanced NSCLC

Faculty: Mark A. Socinski, MD
Executive Medical Director
Member, Thoracic Oncology Program
Florida Hospital Cancer Institute


Dr. Socinski receives grant/research support from Genentech and Pfizer. He is the on the speaker’s bureau for Bristol-Myers Squibb, Celgene and Genentech. His presentation has been peer reviewed.
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Jacquelyn Smith, RN, BSN, MA, CMCN has no real or perceived financial relationships to disclose.
Katie Eads has no real or perceived financial relationships to disclose.
Will Williams has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM. Each physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission on Accreditation.  Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This educational activity is supported by educational grants from
AstraZeneca, Genentech, Lilly USA LLC, and Merck & Company

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue